Femoral artery hemostasis using an implantable device (Angio-Seal™) after coronary angioplasty

✍ Scribed by Kussmaul, William G. ;Buchbinder, Maurice ;Whitlow, Patrick L. ;Aker, Umit T. ;Heuser, Richard R. ;King, Spencer B. ;Kent, Kenneth M. ;Leon, Martin B. ;Kolansky, Daniel M. ;Sandza, Joseph G.

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 405 KB
• Volume: 37
• Category: Article
• ISSN: 0098-6569
• DOI: 10.1002/(sici)1097-0304(199604)37:4<362::aid-ccd3>3.0.co;2-9

✦ Synopsis

Coronary catheter interventional procedures are associated with risk of access site complications. We report our experience with Angio-Seal'", an implantable hemostasis device, when used in the femoral artery after coronary angioplasty procedures. Sixtyeight patients were studied. Their average age was 63 years; 84% of the patients were male. All had 8 French access sheaths and received bolus heparin (mean dose 12,690 U). The arterial sheaths were removed an average of 455 min after the conclusion of the procedure, when the activated clotting time was 220 f 94 sec (range 97-503 sec).

The hemostasis device was successfully deployed in 63 patients (93%). The average time to achieve complete arterial hemostasis was 4.4 f 8.9 min (range 0-45). Immediate, total hemostasis without requiring any form of external pressure was obtained in 37 of these patients (54%):

The Incidence of complications was as follows: Significant bleeding occurred in 9 patients (13%); there were 2 hematomas (3%); there were no vascular or infectious complications. One device embolization occurred when the connecting suture broke and the intravascular anchor was lost; no clinical sequelae resulted, and manual hemostasis was successful. In four other patients, the device did not deploy and was removed entirely, followed by uneventful manual hemostasis. Follow-up for 2 months revealed no late sequelae In any patient, and complete absorption of the device was documented by ultrasound study In all cases.

We conclude that this implantable device can achieve arterial hemostasis quickly and safely when used in anticoagulated patients after coronary lnterventional procedures.